摘要
急性肝衰竭(ALF)和慢加急性肝衰竭(ACLF)病死率高,属于危重病。通过梳理相关文献,从发病机制、中西医治疗现状方面综述ALF和ACLF研究进展。除内科基础治疗、肝脏移植之外,人工肝支持治疗及中医药疗法是肝衰竭的重要研究方向,其中人工肝支持治疗包括双重血浆分子吸附系统(DPMAS)、分子吸附再循环系统(MARS)、成分血浆分离吸附系统(Prometheus)、血浆置换疗法(PE)、血浆透析滤过(PDF)等非生物人工肝及生物人工肝,中医药疗法包括中药汤剂口服、灌肠及中成药的使用。传统中医药疗法与现代生物医学技术相结合,有望进一步发展和完善肝衰竭的治疗手段。
Acute liver failure(ALF)and acute-on-chronic liver failure(ACLF)show high mortality and are critical illnesses.Through sorting out the related literatures,the research progress of ALF and ACLF is reviewed from the aspects of pathogenesis and current situation of traditional Chinese and western medicine treatment.Besides basic medical treatment and liver transplantation,artificial liver support therapy and Chinese medical therapy are important research directions of liver failure.Among,artificial liver support therapies include bioartificial liver and non-bioartificial liver,such as double plasma molecular adsorption system(DPMAS),molecular adsorption recirculation system(MARS),component plasma separation and adsorption system(Prometheus),plasma exchange(PE)therapy and plasma diafiltration(PDF).Chinese medical therapies include oral administration or enema of decoction and application of traditional Chinese patent medicines and simple preparations.The combination of traditional Chinese medical therapy and modern biomedical technology is expected to further develop and improve the treatment methods of liver failure.
作者
许开亮
林兆奋
雷鸣
XU Kailiang;LIN Zhaofen;LEI Ming(Department of Emergency Medicine,Changzheng Hospital,Naval Medical University,Shanghai 200003,China;Intensive Care Unit,Seventh Peopled Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200137,China)
出处
《上海中医药大学学报》
CAS
2021年第3期89-93,共5页
Academic Journal of Shanghai University of Traditional Chinese Medicine
基金
上海中医药大学后备卓越中医人才培养计划项目。
关键词
肝衰竭
急性肝衰竭
慢加急性肝衰竭
人工肝
中药
综述
liver failure
acute liver failure
acute-on-chronic liver failure
artificial liver
Chinese medicine
review
